AstraZeneca PLC (the "Company") today confirmed that the intended ratio change to its NYSE-listed sponsored Level 2 American Depositary Receipt ("ADR") programme announced on 26 June 2015 has now become effective. With effect from 27 July 2015, the Company's American Depositary Share ("ADS") ratio is two (2) ADSs per one (1) Ordinary Share. The former ratio was one (1) ADS per one (1) Ordinary Share. There are no changes to the underlying Ordinary Shares. ADS holders at the close of business New York time on the record date, 22 July 2015, received a distribution of one additional ADS for every ADS held. No action was required by ADS holders to effect this change. Contact details for Citibank, N.A., the Company's ADR depositary, can be found below. A C N Kemp Company Secretary 27 July 2015 CONTACT Citibank Shareholder Services PO Box 43077 Tel (toll free in the US): +1-888-697-8018 Providence Tel (outside the US): +1-781-575-4555 RI 02940-3077 US Media Enquiries Esra Erkal-Paler +44 20 7604 8030 (UK/Global) Jacob Lund +46 8 553 260 20 (Sweden) Michele Meixell + 1 302 885 6351 (US) Investor Enquiries UK Thomas +44 20 7604 8199 mob: +44 7818 524185 Kudsk Larsen Eugenia Respiratory, Inflammation +44 20 7604 8233 mob: +44 7884 735627 Litz and Autoimmunity Nick Cardiovascular andMetabolic +44 1763 263 994 mob: +44 7717 618834 Stone Disease Karl Hård Oncology +44 20 7604 8123 mob: +44 7789 654364 Craig Infection, Neuroscience and +44 20 7604 8591 mob: +44 7881 615764 Marks Gastrointestinal Disease Christer +44 20 7604 8126 mob: +44 7827 836825 Gruvris US Dial / 301-398-3251 866-381-7277 Toll-Free
Confirmation of Change in ADS Ratio
| Source: AstraZeneca PLC